Research outputs
Selected research outputs
- The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation (Journal article - 2022)
- Volatile organic compound analysis of malignant pleural mesothelioma chorioallantoic membrane xenografts. (Journal article - 2024)
- Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening. (Journal article - 2025)
2025
Supplementary Figures S1 to S16 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Figures S1 to S16 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732817
Supplementary Methods and References from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Methods and References from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732811
Supplementary Table S1 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Table S1 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732808
Supplementary Table S2 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Table S2 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732805
Supplementary Table S3 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Table S3 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732802
Supplementary Table S4 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Table S4 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732796
Supplementary Table S5 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2025). Supplementary Table S5 from BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification. doi:10.1158/1541-7786.30732793
Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening.
Schulze, J., Barnett, S., Shaw, L., Herrmann, A., Poptani, H., Rassl, D. M., . . . Coulson, J. M. (2025). Methodology for generating chorioallantoic membrane patient-derived xenograft (CAM-PDX) models of pleural mesothelioma and performing preclinical imaging for the translation of cancer studies and drug screening.. F1000Research, 14, 481. doi:10.12688/f1000research.163596.2
2024
Volatile organic compound analysis of malignant pleural mesothelioma chorioallantoic membrane xenografts.
Little, L. D., Barnett, S. E., Issitt, T., Bonsall, S., Carolan, V. A., Allen, E., . . . Haywood-Small, S. L. (2024). Volatile organic compound analysis of malignant pleural mesothelioma chorioallantoic membrane xenografts.. Journal of breath research, 18(4). doi:10.1088/1752-7163/ad7166
2023
BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification.
Barnett, S. E., Kenyani, J., Tripari, M., Butt, Z., Grosman, R., Querques, F., . . . Coulson, J. M. (2023). BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification.. Molecular Cancer Research. doi:10.1158/1541-7786.mcr-22-0635
2022
The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation
Barnett, S. E., Herrmann, A., Shaw, L., Gash, E. N., Poptani, H., Sacco, J. J., & Coulson, J. M. (2022). The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation. CANCERS, 14(23). doi:10.3390/cancers14235836
2016
Differential sub-nuclear distribution of hypoxia-inducible factors (HIF)-1 and-2 alpha impacts on their stability and mobility
Taylor, S. E., Bagnall, J., Mason, D., Levy, R., Fernig, D. G., & See, V. (2016). Differential sub-nuclear distribution of hypoxia-inducible factors (HIF)-1 and-2 alpha impacts on their stability and mobility. OPEN BIOLOGY, 6(9). doi:10.1098/rsob.160195
2015
HaloTag is an effective expression and solubilisation fusion partner for a range of fibroblast growth factors
Sun, C., Li, Y., Taylor, S. E., Mao, X., Wilkinson, M. C., & Fernig, D. G. (2015). HaloTag is an effective expression and solubilisation fusion partner for a range of fibroblast growth factors. PEERJ, 3. doi:10.7717/peerj.1060
2014
Tight Control of Hypoxia-inducible Factor-α Transient Dynamics Is Essential for Cell Survival in Hypoxia
Bagnall, J., Leedale, J., Taylor, S. E., Spiller, D. G., White, M. R. H., Sharkey, K. J., . . . See, V. (2014). Tight Control of Hypoxia-inducible Factor-α Transient Dynamics Is Essential for Cell Survival in Hypoxia. JOURNAL OF BIOLOGICAL CHEMISTRY, 289(9), 5549-5564. doi:10.1074/jbc.M113.500405
Undated
From single cell to single molecule: elucidation of the intracellular dynamics of the Hypoxia Inducible Factor (HIF)
Taylor, S. (n.d.). From single cell to single molecule: elucidation of the intracellular dynamics of the Hypoxia Inducible Factor (HIF). (PhD Thesis, University of Liverpool).